Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial | Synapse
January 1, 2021Open Access
Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial
Puntos clave
Los puntos clave no están disponibles para este artículo en este momento.
Resumen
Efficacy and Mechanism Evaluation programme from the UK National Institute for Health Research.